AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,178,024 | -58.8% | 102,420 | -61.9% | 0.00% | -50.0% |
| Q2 2023 | $12,553,685 | +15.7% | 268,917 | -5.1% | 0.00% | 0.0% |
| Q1 2023 | $10,846,863 | +68012.2% | 283,516 | -2.4% | 0.00% | -20.0% |
| Q4 2022 | $15,925 | -99.8% | 290,606 | -0.3% | 0.01% | +25.0% |
| Q3 2022 | $9,917,000 | +189.8% | 291,391 | -19.5% | 0.00% | +300.0% |
| Q2 2022 | $3,422,000 | -28.6% | 361,988 | +7.2% | 0.00% | 0.0% |
| Q1 2022 | $4,794,000 | -10.2% | 337,790 | +33.9% | 0.00% | -50.0% |
| Q4 2021 | $5,336,000 | +13.6% | 252,265 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $4,699,000 | -11.9% | 210,246 | -2.2% | 0.00% | 0.0% |
| Q2 2021 | $5,336,000 | +462.9% | 215,062 | +557.8% | 0.00% | – |
| Q1 2021 | $948,000 | -25.5% | 32,694 | -33.7% | 0.00% | – |
| Q4 2020 | $1,273,000 | – | 49,334 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |